



Final Appraisal Recommendation

Advice No: 3214 – October 2014

Certolizumab pegol (Cimzia®) 200 mg solution for injection

Submission by UCB Pharma Ltd

Recommendation of AWMSG

Certolizumab pegol (Cimzia®), in combination with methotrexate, is recommended as an option for use within NHS Wales for the treatment of active psoriatic arthritis in adults when the response to previous disease-modifying antirheumatic drug therapy has been inadequate. Certolizumab pegol can be given as monotherapy in case of intolerance to methotrexate or when continued treatment with methotrexate is inappropriate.

This recommendation applies only in circumstances where the approved Wales Patient Access Scheme is utilised.

Additional note(s):

- Please refer to the Summary of Product Characteristics for the full licensed indication.
- AWMSG noted that certolizumab pegol (Cimzia®) should be used in line with current clinical practice based on national guidelines.

In reaching the above recommendation AWMSG has taken account of the appraisal documentation prepared by the AWMSG Secretariat (reference number 1713), which includes the AWMSG Secretariat Assessment Report (ASAR), the Preliminary Appraisal Recommendation (PAR) and the applicant company's response to the PAR, clinical expert opinion (where available), the views of patients/patient carers (where available) and the lay member perspective.

This recommendation has been ratified by the Minister for Health and Social Services and will be considered for review in three years.

Statement of use: No part of this recommendation may be reproduced without the whole recommendation being quoted in full and cited as:

All Wales Medicines Strategy Group. Final Appraisal Recommendation – 3214:
Certolizumab pegol (Cimzia®) 200 mg solution for injection. October 2014.



NICE has accredited the process used by the All Wales Medicines Strategy Group (AWMSG) to produce its final appraisal recommendation. Accreditation is valid for 5 years from October 2011. More information on accreditation can be viewed at www.evidence.nhs.uk.

For full details on our accreditation visit: www.nice.org.uk/accreditation.